Tasipimidine (Tessie) for Noise Aversion and Separation Anxiety in Dogs

Bottom line

• Tessie (tasipimidine oral solution) became the first FDA-approved treatment for both noise aversion and separation anxiety in dogs on May 6, 2026.[1]
• Tasipimidine is an alpha-2 adrenoceptor agonist; it works by activating alpha-2 receptors in the brain to decrease heightened sympathetic (fight-or-flight) nervous system activity associated with both conditions.[1]
• The product is administered as an oral solution approximately one hour before a noise trigger or before leaving the dog alone; it may be dosed up to three times within 24 hours, with at least three hours between doses.[1]
• Tessie should not be given with food, as food delays absorption; owners should wait at least one hour after feeding before dosing (a small treat to help swallowing is acceptable).[1]
• The active ingredient was authorized in the European Union in October 2021 under EMEA/V/C/005427 before receiving US approval, establishing a multi-year post-authorization safety record.[2]

Drug facts

• Class: Alpha-2 adrenoceptor agonist
• Mechanism: Activates alpha-2 receptors in the brain to decrease heightened sympathetic nervous system activity associated with noise aversion and separation anxiety (per the label)[1]
• Route/interval: Oral solution; approximately 1 hour before trigger; up to 3 doses per 24 hours; minimum 3 hours between doses[1]
• Indication: Treatment of noise aversion and separation anxiety in dogs[1]
• Approval: FDA NADA 141-627, May 6, 2026; EMA EMEA/V/C/005427, October 2021[1][2]
• Label contraindications: Prescription only; veterinary expertise required to diagnose and treat both conditions[1]
• Label common AEs: Not enumerated on the FDA CVM approval page; alpha-2 agonist class effects include sedation and cardiovascular modulation[1]

A specific patient on noise aversion or separation anxiety?

Get an instant cited answer — no signup needed for your first question. Voyage Clinical Desk brings species-specific dose math, monitoring plans, and peer-reviewed evidence to the case in front of you.

Try Voyage Clinical Desk: https://www.thevoyage.ai/forvets/ask?context=tasipimidine-noise-aversion-separation-anxiety-dogs

What the evidence shows

Regulatory background and the dual-indication significance

Before Tessie, managing noise aversion and separation anxiety in dogs required separate drug choices: dexmedetomidine oromucosal gel carried an FDA label for noise aversion, while serotonin-modulating agents such as fluoxetine and clomipramine were approved for separation anxiety. No single product had received clearance for both conditions simultaneously. FDA approval of Tessie on May 6, 2026 (NADA 141-627) under the sponsorship of Orion Corporation of Finland changed that, establishing the first dual indication.[1]

The approval rests partly on an established European safety and regulatory record. Tasipimidine was authorized in the EU by the European Medicines Agency (EMEA/V/C/005427) with an initial decision published October 2021, and was last updated in April 2024 following additional committee review.[2] The EMA classifies tasipimidine under the pharmacotherapeutic group "other hypnotics and sedatives,"[2] reflecting its mechanism of central alpha-2 agonism.

Mechanism of action: alpha-2 adrenoceptor agonism

Alpha-2 adrenoceptor agonists work primarily through presynaptic receptors in the locus coeruleus and throughout the central and peripheral nervous system, suppressing norepinephrine release and attenuating sympathetic outflow. At sedative and anesthetic doses, this class — which includes dexmedetomidine, medetomidine, and xylazine — produces dose-dependent sedation, analgesia, and muscle relaxation. Tasipimidine is formulated at anxiolytic rather than full anesthetic doses to dampen behavioral and physiological fear responses while permitting the dog to remain ambulatory.[1]

The FDA describes the mechanism as "activating specific receptors in a dog's brain to decrease heightened sympathetic nervous system (fight-or-flight) activity associated with noise aversion and separation anxiety."[1] Research on tasipimidine in Beagle dogs has characterized its cardiovascular effects during anesthetic co-administration, confirming that the drug produces alpha-2 agonist-consistent hemodynamic effects (Kastner SB et al. 2024. Vet Anaesth Analg. 51(3):253-265. PMID 38580536).[3]

The clinical overlap between noise aversion and separation anxiety

Both conditions are fear-based behavioral disorders, a shared pathophysiology that underpins the dual indication. Noise aversion is characterized by excessive reactivity to acoustic stimuli — fireworks, thunderstorms, and gunshots are common triggers — producing hiding, vocalization, panting, trembling, urination, defecation, and destructive behavior. Separation anxiety is driven by fear of the owner's absence, triggering a similar behavioral and physiological profile.[1]

The on-demand administration schedule suits both conditions: dosing approximately one hour before a known triggering event (a planned fireworks display, or anticipated departure) rather than requiring months of daily drug loading before effect is detectable. This contrasts with the weeks required for serotonin-modulating agents to reach therapeutic levels, and positions Tessie for situational rather than continuous pharmacological management.[1]

Administration considerations

Tessie is administered as an oral solution one hour before the expected onset of a noise trigger or one hour before departure. Food must be withheld for at least one hour before dosing because food delays absorption, though a small treat used solely to help the dog swallow the solution is acceptable.[1] Up to three doses can be given within 24 hours, with at least three hours separating each dose.[1] Because veterinary diagnosis is required to confirm noise aversion or separation anxiety and to rule out other conditions that may produce similar signs, Tessie is a prescription-only product.[1]

How this fits clinical practice

This section summarizes the labeled indication, pharmacological class context, and practical considerations for practitioners. Dosing for an individual patient must follow the current prescribing information and the clinician's judgment; this page is an evidence summary, not a dosing guide.

Tasipimidine provides an additional option for dogs requiring situational pharmacological support for fear-based disorders. Its oral solution format and the absence of a required food-free window for the small-treat workaround may make owner compliance more accessible than oromucosal gel formulations. The combined indication removes the need to choose between separate products when a dog presents with both conditions.

Given the alpha-2 agonist class, cardiovascular status should be assessed before prescribing, particularly in older dogs or those with pre-existing cardiac disease. Potential additive sedation with other central nervous system depressants should be evaluated on a patient-by-patient basis using the prescribing information. Behavioral modification should be continued alongside pharmacological management wherever feasible.

Voyage Clinical Desk

From clinical question to SOAP draft — cited differentials, live dose calculators, owner handouts. Trained on the veterinary canon (Plumb's, Ettinger, JVIM, ACVIM consensus, 50,000+ indexed references). First answer free, no signup.

Open Voyage Clinical Desk: https://www.thevoyage.ai/forvets/ask?context=tasipimidine-noise-aversion-separation-anxiety-dogs

References

1. U.S. Food and Drug Administration. FDA Approves First Drug to Treat Noise Aversion and Separation Anxiety in Dogs. May 6, 2026. https://www.fda.gov/animal-veterinary/cvm-updates/fda-approves-first-drug-treat-noise-aversion-and-separation-anxiety-dogs
2. European Medicines Agency. Tessie EPAR overview. EMEA/V/C/005427. First published October 2021, last updated April 2024. https://www.ema.europa.eu/en/medicines/veterinary/EPAR/tessie
3. Kastner SB, Amon T, Tunsmeyer J, et al. Effects of tasipimidine premedication with and without methadone and dexmedetomidine on cardiovascular variables during propofol-isoflurane anaesthesia in Beagle dogs. Vet Anaesth Analg. 2024;51(3):253-265. https://pubmed.ncbi.nlm.nih.gov/38580536/

Changelog

• 2026-06-05: First published.

Related reads

• Bedinvetmab (Librela) Adverse Events in Dogs: Neurological Safety Profile